Drug profile · INN
bempedoic acid
NILEMDO
bempedoic acid (NILEMDO) is a atp-citrate synthase inhibitor. Associated with Esperion Therapeutics. Route of administration: oral. Current US regulatory status: approved.
Drug details — bempedoic acid
- US status
- approved
- Class
- Cardiovascular system (C10)
- Route
- ORAL
- Patents
- 20
- Programs
- 16
- Data quality
- 0.89
Quick answer
bempedoic acid (NILEMDO) is a atp-citrate synthase inhibitor. Associated with Esperion Therapeutics. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
ATP-citrate synthase inhibitor
Primary target: ATP-citrate synthase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Related patents
-
US 12404227
Methods of making bempedoic acid and compositions of the same
granted -
US 12398087
Methods of making bempedoic acid and compositions of the same
granted -
US 12344578
Salt forms of bempedoic acid and methods for using the same
granted -
US 11987548
Methods of making bempedoic acid and compositions of the same
granted -
US 11926584
Methods of making bempedoic acid and compositions of the same
granted -
US 11760714
Methods of making bempedoic acid and compositions of the same
granted -
US 11744816
Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
granted -
US 11613511
Methods of making bempedoic acid and compositions of the same
granted -
US 11407705
Methods of making bempedoic acid and compositions of the same
granted -
US 10912751
Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
granted -
US 9610324
Apolipoprotein mixtures
granted -
US 7709515
Compositions comprising ether compounds and pharmaceutical uses therefor
granted -
US 7335799
Hydroxyl compounds and compositions for cholesterol management and related uses
granted -
US 7192940
Ether compounds
granted -
US 6953840
Methods of using non-human animal Apolipoprotein A-I protein
expired -
US 6909014
Intermediates for the synthesis of ether compounds
expired -
US 6831105
Compositions comprising ether compounds and pharmaceutical uses therefor
expired -
US 6790953
Ether compounds
expired -
US 6646170
Intermediates for the synthesis of ether compounds
expired -
US 6506799
Methods of treating cardiovascular diseases, dyslipidemia, dyslipoproteinemia, and hypertension with ether compounds
expired
Frequently asked questions
What is bempedoic acid?
bempedoic acid (NILEMDO) is a atp-citrate synthase inhibitor. Associated with Esperion Therapeutics. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for bempedoic acid?
NILEMDO is a marketed brand name for bempedoic acid. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of bempedoic acid?
bempedoic acid has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.